Impact of cloud deployment on operational expenses of healthcare centers

Healthcare is among the most advanced industries when it comes to embracing and adopting moderntechnology in some way. Cloud computing approaches, in conjunction with the Internet of Things, areadvantageous to extract information from healthcare records. In many cases, cloud computing combinedwith IoT and AI will pave the way for new avenues of medical innovation and insight. Cloud computing'sgrowing acceptance in healthcare extends much beyond simply storing data on cloud infrastructure.Healthcare providers are already embracing this technology to increase efficiency, optimize processes,reduce healthcare costs. The objective of this research was to investigate whether the deployment of cloudcomputing can assist in reducing operational costs in healthcare centers. We used panel data ranging from2008 to 2019 for 156 healthcare centers. The Fixed Effect (FE) model and Random Effect (RE) modelhave been employed. The results suggest that the deployment of cloud computing significantly assists inreducing the operational costs in healthcare centers.

Information Opacity in Biopharmaceutical Innovation Through the Lens of COVID-19

The COVID-19 pandemic has revealed myriad and complex challenges for our national health care system spanning preparedness, response, access, costs, infrastructure, coordination, and medical innovation. These challenges implicate federal, state, and local agencies and actors, as well as international collaborative bodies. One constant throughout the pandemic has been the pressing need for safe and effective diagnostics, prophylactic vaccines, and drug treatments to counter the virus.1 Inarguably, significant problems with the multi-faceted system of drug and vaccine innovation and regulation manifested long before the COVID-19 pandemic.2 The pandemic, however, has laid bare the inextricable connections among federal funding, patents, product review and approval mechanisms, and the eventual medical products and resulting costs.

COVID-19, IP and access: Will the current system of medical innovation and access to medicines meet global expectations?

The COVID-19 pandemic has exposed the fundamental flaws in the current system of medical innovation and access to medicines, which require urgent attention from the global community. This is prompted by the experience of the past decades, which has proven that this system was ineffective in securing adequate access to medicines for all. The understanding of the deficiencies of the existing system is crucial today, as it may help to design effective approaches for improving access. This article will also consider mechanisms that may be implemented by governments for the protection of public health. These include short-term mechanisms, such as compulsory licensing and government use, as well as the long-term design of a new innovation model, including state-coordinated research of medicines and open innovation. The current system should be reconsidered to ensure the prompt development of COVID-19 therapy accessible to everyone and full preparedness for the pandemics of the future.